viewPharmaxis Ltd

Pharmaxis LOXL2 program phase 2 ready after completion of 13-week toxicity studies

The results of the toxicity studies complete Pharmaxis’ scientific package of data for the LOXL2 program.

liver on a human body
Pharmaxis’ LOXL2 inhibitors have the potential to treat fibrotic diseases

Pharmaxis Ltd (ASX:PXS) has now received reports on all of the 13‐week toxicity studies conducted for each of its two Lysyl Oxidase Like 2 (LOXL2) inhibitors.

The company is now ready to enter phase 2 clinical studies for fibrotic diseases such as non‐alcoholic steatohepatitis (NASH), cardiac fibrosis and idiopathic pulmonary fibrosis (IPF).

Adequate safety margin to start phase 2 studies

Both the drug compounds were tested at a range of doses in two species over a 13‐week period to establish the No Observed Adverse Effect Level (NOAEL). 

For both compounds, doses that resulted in 85% or greater inhibition of the target enzyme in the phase 1 studies were below the human equivalent NOAEL doses in all toxicity studies and therefore an adequate safety margin to start phase 2 studies of up to three months in length.  

With the data package complete, Pharmaxis is now conducting a final series of scientific briefings to potential partners.

READ: Pharmaxis resubmits new drug application for Bronchitol in the US

Pharmaxis chief executive officer Gary Phillips said: “The results of the toxicity studies complete our scientific package of data for the LOXL2 program. 

“It is a high quality and comprehensive data package that is a testament to the expertise and experience of the Drug Discovery and Clinical Development teams at Pharmaxis.

READ: Pharmaxis reveals first sales of Aridol® in US following successful relaunch

“We have provided the large pharma companies who have been closely monitoring our progress with the latest study results and are now in the process of supporting them to complete their scientific due diligence. 

“We are keen to answer remaining scientific questions of potential partners, discuss their proposed clinical development strategies should they acquire or license the program and progress discussions concerning appropriate commercial terms.”


Pharmaxis’ LOXL2 program compounds are highly selective small molecule inhibitors of LOXL2 that can be administered orally and the completed pre‐clinical development program supports the potential of both compounds to treat fibrotic disease in one or more organs.

Quick facts: Pharmaxis Ltd

Price: 0.1 AUD

Market: ASX
Market Cap: $39.52 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...



Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) CEO Gary Phillips speaks to Proactive's Andrew Scott after it was announced its US licensee Chiesi Farmaceutici SpA filed a resubmission to the FDA for Bronchitol® . The move addresses issues raised by the US Food and Drug Administration (FDA)...

on 6/5/20

2 min read